MetaCap

Arcutis Biotherapeutics (ARQT) vs Viking Therapeutics (VKTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcutis Biotherapeutics (ARQT) has outperformed Viking Therapeutics (VKTX) over the past year, losing 10.6% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +58.1% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.16 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARQT-10.61%VKTX-27.70%
+26%-5%-37%
Nov 21, 20251 yearNov 20, 2026
ARQT+44.91%VKTX+339.18%
+1486%+661%-165%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARQT versus VKTX key metrics
MetricARQTVKTX
Share price$26.36$24.77
Market cap$3.33B$3.16B
1-day change-2.98%-4.14%
YTD return-9.23%-29.59%
1-year return-10.61%-27.70%
5-year return+58.13%+360.41%
P/E ratio (TTM)119.82—
Forward P/E24.09—
EPS (TTM)$0.22$-5.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$376.07M$0
Revenue growth (YoY)+91.34%—
Net income (latest FY)$-16.14M$-359.64M
Gross margin90.24%—
Operating margin-3.25%—
Net margin-4.29%—
52-week high$34.80$43.10
52-week low$19.30$23.82
Distance from 52-week high-24.25%-42.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.19%+284.82%
Average volume2.58M5.31M
Shares outstanding126.46M127.52M
Employees35474
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARQT has outperformed VKTX by 17.1 percentage points over the past year.

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

About Viking Therapeutics

VKTX stock →

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

ARQT vs VKTX FAQ

Which is bigger, Arcutis Biotherapeutics or Viking Therapeutics?

Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.16B for Viking Therapeutics (VKTX).

Which stock has performed better over the past year, ARQT or VKTX?

ARQT returned -10.61% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.

Are Arcutis Biotherapeutics and Viking Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons